Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?
Background: CDK4/6 inhibitors have become the standard for first-line treatment of metastatic luminal breast cancer based on consistent data from several phase 3 trials demonstrating clinically meaningful improvement of progression-free as well as overall survival. In addition, they are about to bec...
| Publicado en: | Breast Care Vol. 16; no. 2; pp. 115 - 129 |
|---|---|
| Autores principales: | , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Karger AG
2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |